## What is claimed is:

WO 2005/074989

1. A combination which comprises (a) a DNA topoisomerase inhibitor and (b) an IAP inibitor, wherein the active ingredients are present in each case in free form or in the form of a pharmaceutically acceptable salt or any hydrate thereof, and optionally at least one pharmaceutically acceptable carrier; for simultaneous, separate or sequential use.

- 12 -

- 2. A pharmaceutical composition comprising a quantity which is jointly therapeutically effective against a proliferative disease of a combination according to claim 1 and at least one pharmaceutically acceptable carrier.
- 3. Use of a combination as defined in claim 1 for the treatment of a proliferative disease.
- 4. Use of a combination as defined in claim 1 for the preparation of a medicament for the treatment of a proliferative disease.
- 5. Use according to claims 3 or 4 wherein the IAP inhibitor is selected from compound C

and compound D

WO 2005/074989 PCT/EP2005/001180

$$-\frac{1}{N}$$

- 6. Use according to any of claims 3 to 5 wherein the DNA topoisomerase inhibitor is a topoisomease I inhibitor.
- 7. Use according to any of claims 3 to 5 wherein the DNA topoisomerase inhibitor is a topoisomease II inhibitor.
- 8. A method of treating a proliferative disease in a patient, which comprises administering to the patient an effective combination of (a) a DNA topoisomerase inhibitor and (b) an IAP inibitor.
- 9. The method according to claim 8, which comprises administering to the patient an effective combination of (a) a topoisomease I inhibitor and (b) an IAP inibitor.
- 10. A combined preparation, which comprises (a) one or more unit dosage forms of topoisomerase I inhibitor and (b) one or more unit dosage forms of an IAP inhibitor.
- 11. The method according to claim 8, which comprises administering to the patient an effective combination of (a) a topoisomease II inhibitor and (b) an IAP inibitor.
- 12. A combined preparation, which comprises (a) one or more unit dosage forms of topoisomerase II inhibitor and (b) one or more unit dosage forms of an IAP inhibitor.